PALI (Nasdaq)

Palisade Bio
Investor Infomation

Company Overview

Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In clinical studies, LB1148 has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and accelerating the time to return of postoperative bowel function. LB1148 is being investigated in a Phase 2 study to evaluate its effect on post-operative ileus and intra-abdominal adhesions and the return of gastrointestinal function, in subjects undergoing elective bowel resection (PROFILE).

Featured Event

Virtual Investor 2023 Companies to Watch Event

  • Date: January 17, 2023
  • Webcast: Watch

IR Contact


Featured SEC Filings

Email Alerts
Contact IR